

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Broncus Holding Corporation**

**壙博医疗控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2216)**

## **INSIDE INFORMATION TERMINATION OF CONCERT PARTY AGREEMENT**

This announcement is made by Broncus Holding Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

### **BACKGROUND**

Reference is made to the prospectus of the Company dated September 13, 2021 (the “**Prospectus**”). Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

On May 27, 2014, QM12 and BBL entered into an agreement to act in concert pursuant to which they agreed and undertook to act in concert as shareholders of ACL, the Company’s controlling shareholder as of the date of such agreement. At the time, ACL was entitled to control approximately 45.00% of the total issued share capital of the Company before ACL transferred Shares of the Company to its then shareholders on December 17, 2020. Prior to December 17, 2020, ACL was owned as to approximately 50.08% by QM12 and as to approximately 35.62% by BBL. Therefore, QM12 and BBL, acting in concert, had control over the Company through ACL.

On December 17, 2020, QM12 and BBL entered into the Concert Party Agreement, a new concert party agreement, pursuant to which they have agreed to act in concert as Shareholders of the Company in the event that the Company’s Shareholders’ approval is required until the Concert Party Agreement is otherwise terminated. Under the Concert Party Agreement, QM12 and BBL confirmed that they have been acting in concert since May 27, 2014 and have further agreed and undertaken to act in concert as Shareholders of the Company in authorizing or approving key matters of the Group where Shareholders’ approval is required.

As a result of the Concert Party Agreement, QM12 and BBL were considered as a group of shareholders of the Company acting-in-concert. Immediately upon the listing of the Company on the Stock Exchange on September 24, 2021, QM12 and BBL, acting in concert, together with Mr. ZI Zhenjun, Dinova Healthcare (Hong Kong) Co., Limited, BRS Biomedical Limited, Dinova Healthcare Delta Fund (USD) L.P., Xin Nuo Tong Investment Limited, Dinova Venture Partners GP III, L.P. and Dinova Venture Partners GP IV, L.P., were collectively interested in approximately 38.46% of the total issued Shares.

## **TERMINATION OF CONCERT PARTY AGREEMENT**

On August 11, 2023, QM12 and BBL entered into an agreement (the “**Termination Agreement**”) to terminate the Concert Party Agreement pursuant to which QM12 and BBL agreed to cease to act in concert in relation to the affairs and management of the Company with effect from the execution of the Termination Agreement.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares. When in doubt, Shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.**

By Order of the Board  
**Broncus Holding Corporation**  
**ZHAO Michael Yi Wei**  
*Chairman*

Hong Kong, August 11, 2023

*As at the date of this announcement, the Board comprises Mr. ZHAN Guowei and Mr. XU Hong as executive Directors, Mr. ZHAO Michael Yi Wei as Chairman and non-executive Director, Mr. ZI Zhenjun and Mr. ZHANG Ao as non-executive Directors, and Dr. KAM Pok Man, Professor LAU Joseph Wan Yee and Ms. WONG Yee Sin as independent non-executive Directors.*